BUSINESS BRIEFING / PHARMACEUTICALS
- Share via
Pfizer Inc. said it was ending development of two medicines that had been in final human testing to shift funding and staff to other experimental drugs with more potential.
The world’s biggest drug maker said it decided to halt more testing of compounds to treat fibromyalgia and generalized anxiety disorder after reviewing its existing and experimental primary-care drugs. Neither compound had been seen as a likely blockbuster because other drugs to treat those conditions already are on the market.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
